Literature DB >> 26819314

Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.

Takayuki Murata1,2, Chieko Noda2, Yohei Narita3,2, Takahiro Watanabe3, Masahiro Yoshida3, Keiji Ashio3, Yoshitaka Sato3, Fumi Goshima3, Teru Kanda2,4, Hironori Yoshiyama5,6, Tatsuya Tsurumi2, Hiroshi Kimura3.   

Abstract

UNLABELLED: Latent membrane protein 1 (LMP1) is a major oncogene essential for primary B cell transformation by Epstein-Barr virus (EBV). Previous studies suggested that some transcription factors, such as PU.1, RBP-Jκ, NF-κB, and STAT, are involved in this expression, but the underlying mechanism is unclear. Here, we identified binding sites for PAX5, AP-2, and EBF in the proximal LMP1 promoter (ED-L1p). We first confirmed the significance of PU.1 and POU domain transcription factor binding for activation of the promoter in latency III. We then focused on the transcription factors AP-2 and early B cell factor (EBF). Interestingly, among the three AP-2-binding sites in the LMP1 promoter, two motifs were also bound by EBF. Overexpression, knockdown, and mutagenesis in the context of the viral genome indicated that AP-2 plays an important role in LMP1 expression in latency II in epithelial cells. In latency III B cells, on the other hand, the B cell-specific transcription factor EBF binds to the ED-L1p and activates LMP1 transcription from the promoter. IMPORTANCE: Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is crucial for B cell transformation and oncogenesis of other EBV-related malignancies, such as nasopharyngeal carcinoma and T/NK lymphoma. Its expression is largely dependent on the cell type or condition, and some transcription factors have been implicated in its regulation. However, these previous reports evaluated the significance of specific factors mostly by reporter assay. In this study, we prepared point-mutated EBV at the binding sites of such transcription factors and confirmed the importance of AP-2, EBF, PU.1, and POU domain factors. Our results will provide insight into the transcriptional regulation of the major oncogene LMP1.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26819314      PMCID: PMC4810554          DOI: 10.1128/JVI.03227-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma.

Authors:  Loránd L Kis; Natalija Gerasimcik; Daniel Salamon; Emma K Persson; Noémi Nagy; George Klein; Eva Severinson; Eva Klein
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

2.  Modulation of LMP1 protein expression by EBV-encoded microRNAs.

Authors:  Angela Kwok Fung Lo; Ka Fai To; Kwok Wai Lo; Raymond Wai Ming Lung; Jan Wai Ying Hui; Gangling Liao; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

3.  Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines.

Authors:  Michael L Davies; Shushen Xu; James Lyons-Weiler; Adam Rosendorff; Steven A Webber; Laura R Wasil; Diana Metes; David T Rowe
Journal:  Virology       Date:  2010-02-11       Impact factor: 3.616

4.  PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.

Authors:  S Kurahashi; F Hayakawa; Y Miyata; T Yasuda; Y Minami; S Tsuzuki; A Abe; T Naoe
Journal:  Oncogene       Date:  2011-01-10       Impact factor: 9.867

5.  Expression of Epstein-Barr virus-encoded LMP1 and hTERT extends the life span and immortalizes primary cultures of nasopharyngeal epithelial cells.

Authors:  Yim-Ling Yip; Chi-Man Tsang; Wen Deng; Pak-Yan Cheung; Yuesheng Jin; Annie Lai-Man Cheung; Maria Li Lung; Sai-Wah Tsao
Journal:  J Med Virol       Date:  2010-10       Impact factor: 2.327

Review 6.  LMP1 TRAFficking activates growth and survival pathways.

Authors:  Vishal Soni; Ellen Cahir-McFarland; Elliott Kieff
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

7.  Role of a consensus AP-2 regulatory sequence within the Epstein-Barr virus LMP1 promoter in EBNA2 mediated transactivation.

Authors:  Ann Jansson; Pegah Johansson; Weiwen Yang; Lars Palmqvist; Anna Sjöblom-Hallén; Lars Rymo
Journal:  Virus Genes       Date:  2007-06-02       Impact factor: 2.332

8.  Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma.

Authors:  Takayuki Murata; Seiko Iwata; Mohammed Nure Alam Siddiquey; Tetsuhiro Kanazawa; Fumi Goshima; Daisuke Kawashima; Hiroshi Kimura; Tatsuya Tsurumi
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

Review 9.  Nasopharyngeal carcinoma.

Authors:  Bernadette Brennan
Journal:  Orphanet J Rare Dis       Date:  2006-06-26       Impact factor: 4.123

10.  EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas.

Authors:  Kathy H Y Shair; Katherine M Bendt; Rachel H Edwards; Elisabeth C Bedford; Judith N Nielsen; Nancy Raab-Traub
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

View more
  8 in total

1.  Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells.

Authors:  Dhananjay M Nawandar; Makoto Ohashi; Reza Djavadian; Elizabeth Barlow; Kathleen Makielski; Ahmed Ali; Denis Lee; Paul F Lambert; Eric Johannsen; Shannon C Kenney
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.

Authors:  Sophie Beer; Lucas E Wange; Xiang Zhang; Cornelia Kuklik-Roos; Wolfgang Enard; Wolfgang Hammerschmidt; Antonio Scialdone; Bettina Kempkes
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-20       Impact factor: 12.779

3.  Prognostic significance of latent membrane protein 1 expression in non-Hodgkin lymphoma: A meta-analysis.

Authors:  Xiao-Mei Li; Wen-Hua Xiao; Hui-Xia Zhao
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

4.  The Methylation Status and Expression of Epstein-Barr Virus Early Genes BARF1 and BHRF1 in Epstein-Barr Virus-Associated Gastric Carcinomas.

Authors:  Jing Li; Wen Liu; Kui Che; Yan Zhang; Zhenzhen Zhao; Bing Luo
Journal:  Gastroenterol Res Pract       Date:  2017-04-11       Impact factor: 2.260

Review 5.  Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Gui Yang; Qiaoling Deng; Wei Fan; Zheng Zhang; Peipei Xu; Shihui Tang; Ping Wang; Jun'e Wang; Mingxia Yu
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

Review 6.  Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.

Authors:  Takayuki Murata; Atsuko Sugimoto; Tomoki Inagaki; Yusuke Yanagi; Takahiro Watanabe; Yoshitaka Sato; Hiroshi Kimura
Journal:  Viruses       Date:  2021-11-23       Impact factor: 5.048

7.  EBF1 binds to EBNA2 and promotes the assembly of EBNA2 chromatin complexes in B cells.

Authors:  Laura V Glaser; Simone Rieger; Sybille Thumann; Sophie Beer; Cornelia Kuklik-Roos; Dietmar E Martin; Kerstin C Maier; Marie L Harth-Hertle; Björn Grüning; Rolf Backofen; Stefan Krebs; Helmut Blum; Ralf Zimmer; Florian Erhard; Bettina Kempkes
Journal:  PLoS Pathog       Date:  2017-10-02       Impact factor: 6.823

8.  Characterization of a Suppressive Cis-acting Element in the Epstein-Barr Virus LMP1 Promoter.

Authors:  Masahiro Yoshida; Takayuki Murata; Keiji Ashio; Yohei Narita; Takahiro Watanabe; H M Abdullah Al Masud; Yoshitaka Sato; Fumi Goshima; Hiroshi Kimura
Journal:  Front Microbiol       Date:  2017-11-22       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.